AUGUST 21, 2019

NEWS RELEASE

Allied Corp., a Medical Cannabis Company, Provides Production Update and Receives Approval to begin Seed Evaluation in Colombia.
KELOWNA, BRITISH COLUMBIA, CANADA – August 21, 2019 – Allied Corp. (“Allied”) (OTC Markets Pink: ALID) – an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce:
  • ICA approval: Allied has successfully received the approval from ICA to begin the seed evaluation process – https://www.ica.gov.co/?lang=en-US
  • Successful registration of genetics: Allied has successfully registered twenty-four (24) varieties of strains positioned for production
  • Current state of licensing: a report regarding Allied licensing
  • The Allied land consideration: The Allied Colombian land mass and cultivation area description
“Building a venture for long-term success takes a purpose-built solid foundation. Our regulatory approval and production teams have proven themselves as being able to successfully gain the necessary approvals as a foundation to build upon. We are excited to continue to report our successes to our supporters and shareholders.” says Calum Hughes, Founder and CEO.

PRODUCTION

The process to gain approval for seed evaluation in Colombia is very lengthy and extensive. This can include regulated field trials, including thorough data collection and analysis, prior to approval for commercial cultivation. Allied is pleased to announce that they have received approval from ICA (Colombian Institute of Agriculture) to begin the seed evaluation process.Allied is also pleased to announce that they have successfully completed the regulatory process and received strain approval from the technical directorate of the ICA. These registered seeds represent a diverse range of chemotypes, with various ratios of CBD to THC. With this approval, our strains are registered for commercial production; pending the completion of the seed evaluation process. The successful registration of these 24 strains, including our proprietary strains, is a very big milestone for Allied Corp. These approvals evidence the value of our proprietary stabilized seed bank and our capacity to meet local and global market needs easily. We are anticipating imminent approvals for non-psycho active seed evaluation planting. As well, Allied anticipates a near term approval for psycho-active seed evaluation planting.

LICENSING

Allied is also pleased to announce that it has acquired a full suite of licenses in Colombia. Two of the licenses enable Allied to produce cannabis and cannabis derivatives, grow non-psychoactive cannabis (<1% THC), and grow psychoactive cannabis (>1% THC). The third license that Allied has is the extraction and formulation license. This enables Allied to extract cannabinoids from dried flower in anticipation of meeting product demand for oil based products.  Allied is also awaiting final approval of their Canadian Production License from Health Canada. This license has been given the “confirmation of readiness” notice from Health Canada.

LAND

Allied has secured vast agricultural land extension in both Bucamaranga and Ibagué, both key production farming region of Colombia. Both areas have the benefit of having 12 hours of sunlight year-round, temperatures oscillating between 20-30 degrees celsius, with constant humidity. This environment and situation ideal to growing cannabis at low cost.  The Ibague land has an area of 1,400 hectares (about 3,450 acres), all with water rights, an electrical substation, and great paved access to the property. This is situated in close proximity to the free trade zone.
Additional information about Allied Corp. can be found at www.allied.health.
On behalf of the Board,
Calum Hughes
Founder and Chief Executive Officer